Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(100.0%)
3Total
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02125266Phase 1Terminated

Safety and Preliminary Efficacy Study of V404 PDS in Uveitis

Role: lead

NCT01186432Phase 1Completed

Preliminary Safety and Efficacy of the PDS-1.0 in Patients With Neovascular Age Related Macular Degeneration (AMD)

Role: lead

NCT01177644Phase 1Withdrawn

Safety and Preliminary Efficacy Study of PDS-1.0 in Patients With Neovascular AMD

Role: lead

All 3 trials loaded